Krishna Institute of Medical Sciences Ltd
NSE:KIMS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
508.45
789.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Krishna Institute of Medical Sciences Ltd
Krishna Institute of Medical Sciences Ltd. (KIMS) has steadily carved out a significant presence in the Indian healthcare sector, rooted in the ethos of delivering accessible and high-quality care. Emerging from its base in Hyderabad, the institution has expanded its reach through a network of multispecialty hospitals spread across several states in southern and western India. KIMS has built its reputation on providing a broad spectrum of healthcare services, ranging from basic preventive care to advanced super specialty treatments. By blending cutting-edge medical technology with a team of experienced professionals, it has positioned itself as a destination for both domestic and international patients seeking reliable medical solutions.
The financial engine of KIMS runs on its comprehensive service offerings, which cater to a wide range of medical needs. Revenue streams are generated primarily through inpatient and outpatient services, surgical procedures, diagnostic services, and pharmacy sales. By maintaining a focus on operational efficiency and leveraging economies of scale, KIMS has managed to offer competitive pricing, thus broadening its accessibility. Furthermore, the institution has strategically enhanced its profitability through partnerships, expansions, and an emphasis on sustainability within its operations. This approach not only strengthens its market position but also fuels its capability to reinvest in infrastructure, research, and development, aiming for continuous growth and innovation in the healthcare landscape.
Krishna Institute of Medical Sciences Ltd. (KIMS) has steadily carved out a significant presence in the Indian healthcare sector, rooted in the ethos of delivering accessible and high-quality care. Emerging from its base in Hyderabad, the institution has expanded its reach through a network of multispecialty hospitals spread across several states in southern and western India. KIMS has built its reputation on providing a broad spectrum of healthcare services, ranging from basic preventive care to advanced super specialty treatments. By blending cutting-edge medical technology with a team of experienced professionals, it has positioned itself as a destination for both domestic and international patients seeking reliable medical solutions.
The financial engine of KIMS runs on its comprehensive service offerings, which cater to a wide range of medical needs. Revenue streams are generated primarily through inpatient and outpatient services, surgical procedures, diagnostic services, and pharmacy sales. By maintaining a focus on operational efficiency and leveraging economies of scale, KIMS has managed to offer competitive pricing, thus broadening its accessibility. Furthermore, the institution has strategically enhanced its profitability through partnerships, expansions, and an emphasis on sustainability within its operations. This approach not only strengthens its market position but also fuels its capability to reinvest in infrastructure, research, and development, aiming for continuous growth and innovation in the healthcare landscape.
Revenue Growth: KIMS Hospital reported strong Q2 revenue of INR 965 crores, up 23.3% year-on-year and 9.8% quarter-on-quarter.
EBITDA & PAT Decline: Despite revenue growth, EBITDA fell 6.7% YoY and PAT dropped 40.3% YoY due to losses from newly opened hospitals that have yet to break even.
Margins Pressured: EBITDA margin declined to 21.6% from 28.5% YoY, with management expecting margins to stay in the low 20s for the next two quarters before improving as new hospitals ramp up.
Hospital Expansion: Significant bed capacity was added in the past year, with further expansion underway in Telangana, Andhra Pradesh, and new hospitals in Maharashtra and Karnataka.
New Hospital Ramp-Up: Management reiterated that all new hospitals, except one in Bangalore, are expected to be EBITDA neutral within 12 months of commissioning.
Insurance & CGHS: Insurance empanelment delays have affected ramp-up in new markets, but efforts are ongoing; a 15–20% CGHS price hike is expected to benefit margins, with impact seen from Q4.
Cluster Performance: Telangana remains a mature, slower-growth market; Andhra Pradesh shows strong margin expansion, aided by new capacity and acquisitions.
Strategic Focus: KIMS aims to maintain affordable pricing, invest in technology, and expand specialty services to drive volume growth in new markets.